Re: Farmas USA
Hiro, ya entiendo tu post en referencia a BIOD....
Salieron los datos de Fase II para BIOD-123 en relación a HUMALOG, de Eli Lilly...
Biodel's BIOD-123 Achieves Primary Endpoint in Phase 2 Clinical Trial Demonstrating Glycemic Control Comparable to Humalog(R)
Conference Call and Webcast Will be Held Monday, September 9th, at 8:00 a.m. EDT
GlobeNewswirePress Release: Biodel Inc. – 10 hours ago
Email
Print
RELATED QUOTES
Symbol Price Change
BIOD 5.03
DANBURY, Conn., Sept. 8, 2013 (GLOBE NEWSWIRE) -- Biodel Inc. (BIOD) today announced preliminary results from Study 3-201, a Phase 2 clinical study of BIOD-123, an investigational ultra-rapid-acting mealtime insulin, in patients with type 1 diabetes. BIOD-123 achieved the primary endpoint of non-inferiority for HbA1c relative to insulin lispro, a widely prescribed rapid acting mealtime insulin analog marketed as Humalog(R).
Highlights
Compared to Humalog(R), BIOD-123 demonstrated:
Achievement of primary efficacy endpoint; demonstration of non-inferiority in change from baseline HbA1c
Comparable weight gain, mean hypoglycemia event rates and postprandial glucose excursions over the entire treatment period with some notable trends in favor of BIOD-123 in weight gain during the stable dosing period, median hypoglycemia event rates and postprandial glucose excursions to a liquid meal challenge test
Comparable safety and adverse event profiles with the exception of an increased frequency of injection site pain associated with BIOD-123 which appears to be clinically minor, was short-lived and did not result in patient dropouts